Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-06

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine and naloxone from Dr. Reddy's Laboratories, enabling a generic product for the treatment of opioid use…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)